leadf
logo-loader
viewMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals posts strong revenue numbers, trend to continue in 2019

Medexus Pharmaceuticals Inc (TSXV:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive Investors the Canadian company posted fiscal fourth-quarter results, with revenue that more than quintupled year-over-year.

d’Entremont says the drug-maker saw revenue jump to $12.7 million, up from $2.1 million in the prior-year quarter due to its recent M&A activity and revenues coming from its pharma products.

Quick facts: Medexus Pharmaceuticals Inc

Price: 4.2 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $60.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Medexus Pharmaceuticals gets Health Canada approval to market Gleolan for...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) CEO Ken d’Entremont tells Proactive the group has received a notice of compliance from Health Canada, granting the company approval to market its tumor imaging agent Gleolan in the country. d’Entremont says with Gleolan, which is essentially...

1 week, 4 days ago

2 min read